drugset
drugset / Trial / NCT04742101

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

NCT04742101 ↗

Phase 1/2 Completed 57 enrolled Servier ADIR, a Servier Group company · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.

Timeline

Start
2021-03-10
Primary completion
2026-03-27
Completion
2026-03-27

Publications

  • Background Pierola AA, De Botton S, Jan JH, Campbell V, O'Nions J, Calbacho M, Ervin-Hayes AL, Keagle K, Maillard A, Beneton M, Romagnoli M, Broniscer A. Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment. Blood. 2023 Nov 2;142(Supplement 1):1555. doi: https://doi.org/10.1182/blood-2023-180795

Drugs

EvaluationDrugModalityDoseRoute
Subject VOB560 Small molecule — Intravenous
Background Azacitidine Other / unclassified — Subcutaneous

Indications

acute myeloid leukemia